| Description |
LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma[1].
|
| Related Catalog |
|
| Target |
EC50: 0.095 ± 0.012 μM (LXRβ) 0.277 ± 0.066 μM (LXRα)[1]
|
| In Vivo |
LXRβ agonist-3 (compound 4-13) (BALB/c mice, 50 mg/kg, IP, daily for 15 days) significantly reduces glioblastoma tumor growth[1].
|
| References |
[1]. Chen H, Chen Z, Zhang Z, Li Y, Zhang S, Jiang F, Wei J, Ding P, Zhou H, Gu Q, Xu J. Discovery of new LXRβ agonists as glioblastoma inhibitors. Eur J Med Chem. 2020 May 15;194:112240.
|
